Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × ALK-positive NSCLC × Crizotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 13 Neoplasms 1 Multiple Endocrine Neoplasia Type 2a 1 Lung Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Large Cell 1 Carcinoma 1 Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1 Adenocarcinoma 1 ALK-positive NSCLC 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04009317 2019-10-30

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Unknown

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡